TY - JOUR
T1 - Lymphoid antigens (LY) on leukaemic cell populations
T2 - Recognition by means of antilymphocytic globulins and clinical implications
AU - Marmont, Alberto M.
AU - Santini, Gino
AU - Piaggio, Giovanna
AU - Raffo, Maria R.
AU - Damasio, Eugenio
AU - Carella, Michele
AU - Rossi, Edoardo
AU - Giordano, Domenico
AU - Cerri, Raffaella
AU - van Lint, Maria T.
AU - Vimercati, Renato
AU - Risso, Marco
AU - Podesta, Marina
AU - Bacigalupo, Andrea
PY - 1979
Y1 - 1979
N2 - Cells obtained from 120 cases of acute and chronic leukaemias (both non-lymphocytic, ANL, and lymphoid leukaemias, ALL) were reacted in an indirect immunofluorescence test with antilymphocytic globulins (ALG) directed against different lymphoid cell populations (spleen, lymph node, tonsil, thymus, thoracic duct, peripheral blood lymphocytes, chronic lymphatic leukaemias cells and cultured lymphoblasts). The aim of this study was to recognize lymphoid antigens expressed on both thymus and bone marrow derived lymphocytes, as well as on leukaemic cells. Our 4 years' experience can be summarized as follows: (1) unabsorbed ALGs strongly react with B, T cells, as well as with all leukaemic cells tested; (2) myeloid cross-reactivity can be overcome after proper absorptions with cells from AML or AMoL or CML or with neutrophils from healthy donors; (4) MY-absorbed ALG can still interact with B, T lymphocytes, CLL-cells, blasts from B, T, null ALL and cells from CML in lymphoid blastic crisis, but not with myeloid or monocytic cells; (5) four out of five undifferentiated leukaemias proved to be reactive to ALG, as well as four out of 31 AML. All ALG-positive cases (LY+ cases), irrespective of their cytochemical diagnosis, were treated with vincristine-prednisone, with good response rates. The biological and clinical significance of these results are discussed.
AB - Cells obtained from 120 cases of acute and chronic leukaemias (both non-lymphocytic, ANL, and lymphoid leukaemias, ALL) were reacted in an indirect immunofluorescence test with antilymphocytic globulins (ALG) directed against different lymphoid cell populations (spleen, lymph node, tonsil, thymus, thoracic duct, peripheral blood lymphocytes, chronic lymphatic leukaemias cells and cultured lymphoblasts). The aim of this study was to recognize lymphoid antigens expressed on both thymus and bone marrow derived lymphocytes, as well as on leukaemic cells. Our 4 years' experience can be summarized as follows: (1) unabsorbed ALGs strongly react with B, T cells, as well as with all leukaemic cells tested; (2) myeloid cross-reactivity can be overcome after proper absorptions with cells from AML or AMoL or CML or with neutrophils from healthy donors; (4) MY-absorbed ALG can still interact with B, T lymphocytes, CLL-cells, blasts from B, T, null ALL and cells from CML in lymphoid blastic crisis, but not with myeloid or monocytic cells; (5) four out of five undifferentiated leukaemias proved to be reactive to ALG, as well as four out of 31 AML. All ALG-positive cases (LY+ cases), irrespective of their cytochemical diagnosis, were treated with vincristine-prednisone, with good response rates. The biological and clinical significance of these results are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0018690096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018690096&partnerID=8YFLogxK
U2 - 10.1016/0145-2126(79)90057-2
DO - 10.1016/0145-2126(79)90057-2
M3 - Article
C2 - 93177
AN - SCOPUS:0018690096
VL - 3
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 5
ER -